(Q38265085)

1 September 2017

1 reference

title

PASI90 response: the new standard in therapeutic efficacy for psoriasis (English)

1 reference

1 September 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25370811%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

L Puig

series ordinal

1

1 reference

1 September 2017

language of work or name

1 reference

4 November 2014

1 reference

Journal of the European Academy of Dermatology and Venereology

1 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25370811%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25370811%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25370811%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

645-648

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25370811%20AND%20SRC:MED&resulttype=core&format=json

What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature

7 June 2020

cites work

1 reference

Translating the science of quality of life into practice: What do dermatology life quality index scores mean?

21 January 2018

1 reference

Definition of treatment goals for moderate to severe psoriasis: a European consensus

21 January 2018

1 reference

The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis

21 January 2018

1 reference

Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.

21 January 2018

1 reference

Implementing treatment goals for successful long-term management of psoriasis

21 January 2018

1 reference

The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab

21 January 2018

1 reference

Why statistics matter: limited inter-rater agreement prevents using the psoriasis area and severity index as a unique determinant of therapeutic decision in psoriasis

21 January 2018

1 reference

Strategies for improving the quality of care in psoriasis with the use of treatment goals--a report on an implementation meeting

21 January 2018

1 reference

21 January 2018

1 reference

Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary.

21 January 2018

1 reference

Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.

21 January 2018

1 reference

Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab

21 January 2018

1 reference

Secukinumab in plaque psoriasis--results of two phase 3 trials

21 January 2018

1 reference

Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients

21 January 2018

1 reference

Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis con agentes biológicos, 2013. I. Consideraciones de eficacia y selección del tratamiento

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JDV.12817

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25370811%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

1 reference